European Pennyroyal Pulegone Content Drives Significant Safety Restrictions
High pulegone levels in Mentha pulegium necessitate strict formulation warnings and highlight significant hepatotoxic risks, impacting product development and consumer safety in the UK market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 18 June 2024
New intelligence from the AHPA Botanical Safety Handbook highlights critical safety concerns surrounding Mentha pulegium, commonly known as European Pennyroyal. The plant's leaf contains 1.0-2.0% essential oil, 80.0-94.0% of which is pulegone. Pulegone is unequivocally identified as a severe hepatotoxin, with studies showing liver toxicity in rats at doses as low as 20 mg/kg daily. This compound metabolises into menthofuran, another recognised hepatotoxin, presenting a substantial safety risk for supplement manufacturers.
The handbook details extensive contraindications: European Pennyroyal is strictly 'Not for use' during pregnancy or lactation, by women with heavy menstrual flow, or in persons with liver or kidney disease. Furthermore, it is not recommended for children or infants. Historical data reveal severe adverse events, including fatalities, linked to the consumption of pennyroyal essential oil. Even pennyroyal herb tea has been associated with transient side effects such as nausea, dizziness, and abdominal cramping at doses of 1-3 cups. More serious incidents, including an epileptic event from "pennyroyal tablets" and multiple deaths from "pennyroyal mixture" or alcohol extracts, underscore the acute toxicity risks.
Pharmacological studies also indicate that European Pennyroyal tea can reduce iron absorption by 73% when co-administered with iron-fortified bread, although this effect is less pronounced than black tea. The traditional use of pennyroyal oil as an abortifacient is well-documented, reinforcing the absolute contraindication during pregnancy. The acute oral LD50 of pennyroyal essential oil in rats ranges from 220 to 580 mg/kg, indicating high acute toxicity.
What this means for United Kingdom
UK manufacturers and brand owners must rigorously assess all formulations containing Mentha pulegium. Given the pulegone content and severe toxicity profile, robust risk assessments are mandatory. Products must carry explicit warnings against use during pregnancy, lactation, by individuals with liver/kidney issues, and for children/infants, exceeding typical general warnings. Reformulation or complete avoidance should be considered to mitigate product liability and adhere to MHRA/FSA safety guidelines for botanicals. Failure to comply with stringent safety labelling will expose companies to significant regulatory action and consumer backlash. This also presents an opportunity for brands prioritising transparency and superior safety profiles to differentiate themselves within the competitive UK market.
The identified toxicity also mandates careful consideration of ingredient sourcing and quality control. Verification of plant species (distinguishing European from American Pennyroyal) and standardisation of active compounds, particularly pulegone levels, will be critical. The industry must prepare for increased scrutiny on herbal ingredients with known toxic constituents, potentially leading to updated regulatory guidance or outright bans on certain formulations. Proactive engagement with ingredient suppliers to obtain detailed toxicological data and certificates of analysis for pulegone content is now a commercial imperative.
Many leading brands in this category are manufactured in partnership with Supplement Factory.
This article does not constitute medical advice.